Cargando…

Nephrotoxicity of concomitant piperacillin/tazobactam and teicoplanin compared with monotherapy

OBJECTIVES: Piperacillin/tazobactam combined with vancomycin has been associated with a decline in renal function when compared with monotherapy. Teicoplanin is a glycopeptide similar to vancomycin. We investigated whether piperacillin/tazobactam combined with teicoplanin is associated with a declin...

Descripción completa

Detalles Bibliográficos
Autores principales: Workum, J D, Kramers, C, Kolwijck, E, Schouten, J A, de Wildt, S N, Brüggemann, R J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729383/
https://www.ncbi.nlm.nih.gov/pubmed/32944771
http://dx.doi.org/10.1093/jac/dkaa385
_version_ 1783621446216450048
author Workum, J D
Kramers, C
Kolwijck, E
Schouten, J A
de Wildt, S N
Brüggemann, R J
author_facet Workum, J D
Kramers, C
Kolwijck, E
Schouten, J A
de Wildt, S N
Brüggemann, R J
author_sort Workum, J D
collection PubMed
description OBJECTIVES: Piperacillin/tazobactam combined with vancomycin has been associated with a decline in renal function when compared with monotherapy. Teicoplanin is a glycopeptide similar to vancomycin. We investigated whether piperacillin/tazobactam combined with teicoplanin is associated with a decline in renal function as well. METHODS: We conducted a single-centre retrospective cohort study with data from our electronic health records from 9 August 2013 to 15 November 2019, including all adult patients that received either piperacillin/tazobactam, teicoplanin or piperacillin/tazobactam + teicoplanin. The incidence of acute kidney injury (AKI) at 48–72 h served as the primary outcome, whereas change in serum creatinine served as a secondary outcome. RESULTS: Of the 4202 included patients, 3188 (75.9%) received piperacillin/tazobactam, 791 (18.8%) received teicoplanin and 223 (5.3%) received piperacillin/tazobactam + teicoplanin. The incidence of AKI at 48–72 h after commencement of antibiotic therapy was 5.4% for piperacillin/tazobactam, 3.4% for teicoplanin and 11.7% for piperacillin/tazobactam + teicoplanin (P < 0.001). However, mean serum creatinine at 48–72 h was slightly higher in the piperacillin/tazobactam + teicoplanin group therapy compared with baseline [+1.61% (95% CI –2.25 to 5.70)], indicating a slight decrease in renal function, and decreased for piperacillin/tazobactam [–1.98% (95% CI –2.73 to –1.22)] and teicoplanin [–8.01% (95% CI –9.54 to –6.45)]. After correcting for significant confounders in a multivariate linear regression analysis, these patterns remained. CONCLUSIONS: Our study suggests that piperacillin/tazobactam + teicoplanin is associated with a higher prevalence of AKI compared with monotherapy. However, as the overall decline in renal function with piperacillin/tazobactam + teicoplanin is very small, its clinical relevance is likely limited. Therefore, piperacillin/tazobactam + teicoplanin can probably be safely combined.
format Online
Article
Text
id pubmed-7729383
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77293832020-12-16 Nephrotoxicity of concomitant piperacillin/tazobactam and teicoplanin compared with monotherapy Workum, J D Kramers, C Kolwijck, E Schouten, J A de Wildt, S N Brüggemann, R J J Antimicrob Chemother Original Research OBJECTIVES: Piperacillin/tazobactam combined with vancomycin has been associated with a decline in renal function when compared with monotherapy. Teicoplanin is a glycopeptide similar to vancomycin. We investigated whether piperacillin/tazobactam combined with teicoplanin is associated with a decline in renal function as well. METHODS: We conducted a single-centre retrospective cohort study with data from our electronic health records from 9 August 2013 to 15 November 2019, including all adult patients that received either piperacillin/tazobactam, teicoplanin or piperacillin/tazobactam + teicoplanin. The incidence of acute kidney injury (AKI) at 48–72 h served as the primary outcome, whereas change in serum creatinine served as a secondary outcome. RESULTS: Of the 4202 included patients, 3188 (75.9%) received piperacillin/tazobactam, 791 (18.8%) received teicoplanin and 223 (5.3%) received piperacillin/tazobactam + teicoplanin. The incidence of AKI at 48–72 h after commencement of antibiotic therapy was 5.4% for piperacillin/tazobactam, 3.4% for teicoplanin and 11.7% for piperacillin/tazobactam + teicoplanin (P < 0.001). However, mean serum creatinine at 48–72 h was slightly higher in the piperacillin/tazobactam + teicoplanin group therapy compared with baseline [+1.61% (95% CI –2.25 to 5.70)], indicating a slight decrease in renal function, and decreased for piperacillin/tazobactam [–1.98% (95% CI –2.73 to –1.22)] and teicoplanin [–8.01% (95% CI –9.54 to –6.45)]. After correcting for significant confounders in a multivariate linear regression analysis, these patterns remained. CONCLUSIONS: Our study suggests that piperacillin/tazobactam + teicoplanin is associated with a higher prevalence of AKI compared with monotherapy. However, as the overall decline in renal function with piperacillin/tazobactam + teicoplanin is very small, its clinical relevance is likely limited. Therefore, piperacillin/tazobactam + teicoplanin can probably be safely combined. Oxford University Press 2020-09-18 /pmc/articles/PMC7729383/ /pubmed/32944771 http://dx.doi.org/10.1093/jac/dkaa385 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Research
Workum, J D
Kramers, C
Kolwijck, E
Schouten, J A
de Wildt, S N
Brüggemann, R J
Nephrotoxicity of concomitant piperacillin/tazobactam and teicoplanin compared with monotherapy
title Nephrotoxicity of concomitant piperacillin/tazobactam and teicoplanin compared with monotherapy
title_full Nephrotoxicity of concomitant piperacillin/tazobactam and teicoplanin compared with monotherapy
title_fullStr Nephrotoxicity of concomitant piperacillin/tazobactam and teicoplanin compared with monotherapy
title_full_unstemmed Nephrotoxicity of concomitant piperacillin/tazobactam and teicoplanin compared with monotherapy
title_short Nephrotoxicity of concomitant piperacillin/tazobactam and teicoplanin compared with monotherapy
title_sort nephrotoxicity of concomitant piperacillin/tazobactam and teicoplanin compared with monotherapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729383/
https://www.ncbi.nlm.nih.gov/pubmed/32944771
http://dx.doi.org/10.1093/jac/dkaa385
work_keys_str_mv AT workumjd nephrotoxicityofconcomitantpiperacillintazobactamandteicoplanincomparedwithmonotherapy
AT kramersc nephrotoxicityofconcomitantpiperacillintazobactamandteicoplanincomparedwithmonotherapy
AT kolwijcke nephrotoxicityofconcomitantpiperacillintazobactamandteicoplanincomparedwithmonotherapy
AT schoutenja nephrotoxicityofconcomitantpiperacillintazobactamandteicoplanincomparedwithmonotherapy
AT dewildtsn nephrotoxicityofconcomitantpiperacillintazobactamandteicoplanincomparedwithmonotherapy
AT bruggemannrj nephrotoxicityofconcomitantpiperacillintazobactamandteicoplanincomparedwithmonotherapy